ANTX

AN2 Therapeutics, Inc.

Investor Moves

InvestorPortfolio ValuePortfolio ChangePosition ChangeAvg Buy PriceCurrent Price
Ken GriffinCitadel Advisors
$531k155.2k shares
AddQ1 2026
$399k
$3.42
$4.46
Jim SimonsRenaissance Technologies
$680k198.8k shares
AddQ1 2026
$294k
$3.42
$4.46
Jim SimonsRenaissance Technologies
$386k338.6k shares
TrimQ4 2025
$104k
$1.14
$4.46
Jim SimonsRenaissance Technologies
$66.9K
AddQ3 2025
$67k
--
$4.46
Jim SimonsRenaissance Technologies
$-78.7K
TrimQ2 2025
$79k
--
$4.46
Jim SimonsRenaissance Technologies
$-298.6K
TrimQ1 2025
$299k
--
$4.46

News

businesswire.comAN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Diseasebusinesswire.comJun 4businesswire.comAN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conferencebusinesswire.comMay 21businesswire.comAN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlightsbusinesswire.comMay 11businesswire.comAN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forumbusinesswire.comMay 7businesswire.comAN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Diseasebusinesswire.comMar 31